Lille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The company will reprioritise its (preclinical) pipeline, including VS-01, which will be further developed in the area of urea cycle disorder (UCD).
UniQure’s stocks up after AMT-130 trial win
Latest NewsAmsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for marketing authorisation next year. In addition, UniQure entered into a US$175m non-dilutive senior secured term loan facility with Hercules Capital and commenced a US$200m underwritten public offering of its ordinary shares to prepare a BLA in Q1 2026.
Siemens Healthineers enters CRISPR diagnostics space
Latest NewsSiemens Healthineers have participated in a US$25m Series A extension of the CRISPR diagnostics specialist VedaBio Inc and signed a strategic agreement.
Revyve scaling up production by €24m financing
Latest NewsWageningen-based food-tech scale-up Revyve has raised €24m in a Series B financing, bringing its total capital raised to more than €40 million. The company will use the proceeds to scale up its yeast-based egg replacement to the 1,600 t/a scale.
Roche moves obesity asset CT-388 into Phase III
Latest NewsSwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by 2030, Roche Pharma CEO Teresa Graham said at Roche’s Pharma Day in London.
Genfit SA discontinues lead programme
Latest NewsLille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The company will reprioritise its (preclinical) pipeline, including VS-01, which will be further developed in the area of urea cycle disorder (UCD).
Mondego Bio kicks off with Series A financing
Latest NewsLisbon’s immuno-oncology company Mondego Bio Lda has left stealth mode through a Series A financing led by Biovance Capital, supported by OrbiMed and Torrey Pines.
Whitepaper Plastic Injection Molding in Cleanrooms
Products, sliderDue to its properties, plastic is a sought-after material for medical technology components. Depending on the specification, the manufacturing of these components is subject to strict hygiene measures. The whitepaper from RKT shows what is important in plastic injection molding and the assembly of components under cleanroom conditions.
Roche acquires 89bio for US$3.5bn
Latest NewsRoche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.
CSL backs VarmX in US$2.2bn deal
Latest NewsCSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001.
Enhanced Genomics raises US$19m
Latest NewsBritish Enhanced Genomics Ltd has extended its Series A funding to US$19m. Investors include BGF, Parkwalk, and Meltwind.